Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Pioneering Oxford research to tackle vision loss is set to feature on the BBC’s One Show this week.

The BBC One programme is to feature the story of a patient from Reading who has choroideremia, a progressive loss of vision.

The patient took part in an ongoing gene therapy trial that is being performed at the John Radcliffe Hospital by the Nuffield Laboratory of Ophthalmology, led by University of Oxford Professor and OUH Consultant Ophthalmologist Robert MacLaren.

Choroideremia is a currently incurable genetic eye disorder caused by a mutation in a single gene.The new treatment seeks to replace a ‘normal’ version of that gene, offering the potential to halt or even partially reverse vision loss.

The treatment is delivered to the eye by an injection, underneath the retina, of a virus that contains the correct version of the gene. The injection places the viral particles in the correct anatomical location, and the virus itself delivers the correct copy of the gene into the dysfunctional cells.

A number of patients in this ongoing trial have already been enrolled and received gene therapy. If successful, this technique may be applied more widely to other genetic retinal diseases.

The programme is planned to broadcast on Wednesday, July 8 from 7pm.

Similar stories

New insights gained into how the brain encodes information about the world

Scientists have developed a new way to test the theory that active neurons can change what they signal in the world, rather than keeping a stable correspondence to things (such as a features of an object, or ideas).

Oxford and Quinnipiac researchers discuss integrated clinical care, education, and research in multiple sclerosis

Mount Sinai Rehabilitation Hospital's Mandell Center for Multiple Sclerosis Care and Neuroscience Research welcomed University of Oxford partners in September. Stakeholders from University of Oxford and Quinnipiac University met to discuss ongoing research and future opportunities to develop a Mandell MS Center concept of care in the UK.

Royal Academy of Engineering Research Fellowship

Dr Rezvan Farahibozorg has received one of 17 Royal Academy of Engineering Research Fellowships for 2022.

Three New Professors

Many congratulations to the following members of our Department who have been awarded the title of Professor in the recent Recognition of Distinction round.

Repurposed drug could help patients with motor neuron disease

A drug typically used to treat enlarged prostates and high blood pressure has shown promise as a potential new therapy for motor neuron disease (MND), according to a new study.

Finding out more about Parkinson’s by monitoring symptoms at home

Professor Chrystalina Antoniades explains how the COVID pandemic accelerated an innovation in one research project into Parkinson's Disease.